Zobrazeno 1 - 10
of 151
pro vyhledávání: '"Udayan, Guha"'
Autor:
Xu Zhang, Sudipto Das, Zhiya Yu, Ken-ichi Hanada, James C Yang, Thorkell Andresson, Catherine M Ade, Matthew J Sporn, Yue A Qi, Tapan Maity, Udayan Guha
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 9 (2023)
Background Tumor-specific mutated proteins can create immunogenic non-self, mutation-containing ‘neoepitopes’ that are attractive targets for adoptive T-cell therapies. To avoid the complexity of defining patient-specific, private neoepitopes, th
Externí odkaz:
https://doaj.org/article/58a08e7c3c1e4ebdb8cc548abf290a85
Autor:
Delphine Lissa, Nobuyuki Takahashi, Parth Desai, Irena Manukyan, Christopher W. Schultz, Vinodh Rajapakse, Moises J. Velez, Deborah Mulford, Nitin Roper, Samantha Nichols, Rasa Vilimas, Linda Sciuto, Yuanbin Chen, Udayan Guha, Arun Rajan, Devon Atkinson, Rajaa El Meskini, Zoe Weaver Ohler, Anish Thomas
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-16 (2022)
Molecular subtypes of small cell lung cancer characterized by neuroendocrine differentiation have been described in cell lines and primary tumors. The clinical implications of neuroendocrine subtypes in metastatic and relapsed tumors, and the extent
Externí odkaz:
https://doaj.org/article/2b706f2be3074f5d81c7957af90cea3c
Autor:
Behdokht Jan Fada, Udayan Guha, Yi Zheng, Eleazar Reward, Elie Kaadi, Ayette Dourra, Haidong Gu
Publikováno v:
Viruses, Vol 15, Iss 5, p 1070 (2023)
Upon viral entry, components of ND10 nuclear bodies converge with incoming DNA to repress viral expression. The infected cell protein 0 (ICP0) of herpes simplex virus 1 (HSV-1) contains a RING-type E3 ubiquitin ligase that targets the ND10 organizer,
Externí odkaz:
https://doaj.org/article/15f68de4b94c4d41a506be90d2cb194c
Autor:
Fraser D. Johnson, John Ferrarone, Alvin Liu, Christina Brandstädter, Ravi Munuganti, Dylan A. Farnsworth, Daniel Lu, Jennifer Luu, Tianna Sihota, Sophie Jansen, Amy Nagelberg, Rocky Shi, Giovanni C. Forcina, Xu Zhang, Grace S.W. Cheng, Sandra E. Spencer Miko, Georgia de Rappard-Yuswack, Poul H. Sorensen, Scott J. Dixon, Udayan Guha, Katja Becker, Hakim Djaballah, Romel Somwar, Harold Varmus, Gregg B. Morin, William W. Lockwood
Publikováno v:
Cell Reports, Vol 38, Iss 6, Pp 110343- (2022)
Summary: Phenotype-based screening can identify small molecules that elicit a desired cellular response, but additional approaches are required to characterize their targets and mechanisms of action. Here, we show that a compound termed LCS3, which s
Externí odkaz:
https://doaj.org/article/777c0ebba6e744a58fb41d6fac2350cb
Autor:
Arun Rajan, Christopher R. Heery, Anish Thomas, Andrew L. Mammen, Susan Perry, Geraldine O’Sullivan Coyne, Udayan Guha, Arlene Berman, Eva Szabo, Ravi A. Madan, Leomar Y. Ballester, Stefania Pittaluga, Renee N. Donahue, Yo-Ting Tsai, Lauren M. Lepone, Kevin Chin, Fiona Ginty, Anup Sood, Stephen M. Hewitt, Jeffrey Schlom, Raffit Hassan, James L. Gulley
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-12 (2019)
Abstract Background Thymic epithelial tumors are PD-L1–expressing tumors of thymic epithelial origin characterized by varying degrees of lymphocytic infiltration and a predisposition towards development of paraneoplastic autoimmunity. PD-1–target
Externí odkaz:
https://doaj.org/article/b66a3a1a163041f19fe2d792850a4a64
Autor:
Ning Li, Udayan Guha, Chul Kim, Leah Ye, Jordan Cheng, Feng Li, David Chia, Fang Wei, David T. W. Wong
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Background: The longitudinal monitoring of actionable oncogenes in circulating tumor DNA (ctDNA) of non-small cell lung cancer (NSCLC) is crucial for clinicians to evaluate current therapeutic response and adjust therapeutic strategies. Saliva-based
Externí odkaz:
https://doaj.org/article/4abc7462806d40e2afdf8ff57deee053
Autor:
Nitin Roper, Anna-Leigh Brown, Jun S. Wei, Svetlana Pack, Christopher Trindade, Chul Kim, Olivia Restifo, Shaojian Gao, Sivasish Sindiri, Farid Mehrabadi, Rajaa El Meskini, Zoe Weaver Ohler, Tapan K. Maity, Abhilash Venugopalan, Constance M. Cultraro, Elizabeth Akoth, Emerson Padiernos, Haobin Chen, Aparna Kesarwala, DeeDee K. Smart, Naris Nilubol, Arun Rajan, Zofia Piotrowska, Liqiang Xi, Mark Raffeld, Anna R. Panchenko, Cenk Sahinalp, Stephen Hewitt, Chuong D. Hoang, Javed Khan, Udayan Guha
Publikováno v:
Cell Reports Medicine, Vol 1, Iss 1, Pp 100007- (2020)
Summary: Clonal evolution of osimertinib-resistance mechanisms in EGFR mutant lung adenocarcinoma is poorly understood. Using multi-region whole-exome and RNA sequencing of prospectively collected pre- and post-osimertinib-resistant tumors, including
Externí odkaz:
https://doaj.org/article/bd88b4540b1e47469281d9cfc6d07cbc
Publikováno v:
Data in Brief, Vol 19, Iss , Pp 424-436 (2018)
The data presented here describes the use of targeted proteomic assays to quantify potential biomarkers of Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) sensitivity in lung adenocarcinoma and is related to the research artic
Externí odkaz:
https://doaj.org/article/7c456235919b49579c1b066260439934
Autor:
Nitin Roper, Shaojian Gao, Tapan K. Maity, A. Rouf Banday, Xu Zhang, Abhilash Venugopalan, Constance M. Cultraro, Rajesh Patidar, Sivasish Sindiri, Anna-Leigh Brown, Alexander Goncearenco, Anna R. Panchenko, Romi Biswas, Anish Thomas, Arun Rajan, Corey A. Carter, David E. Kleiner, Stephen M. Hewitt, Javed Khan, Ludmila Prokunina-Olsson, Udayan Guha
Publikováno v:
Cell Reports, Vol 26, Iss 10, Pp 2651-2666.e6 (2019)
Summary: Intratumor mutational heterogeneity has been documented in primary non-small-cell lung cancer. Here, we elucidate mechanisms of tumor evolution and heterogeneity in metastatic thoracic tumors (lung adenocarcinoma and thymic carcinoma) using
Externí odkaz:
https://doaj.org/article/a89fb160e8244d76991306067b2f929e
Autor:
Tapan K. Maity, Eun Young Kim, Constance M. Cultraro, Abhilash Venugopalan, Leena Khare, Ramulu Poddutoori, Sivapriya Marappan, Samiulla D. Syed, William G. Telford, Susanta Samajdar, Murali Ramachandra, Udayan Guha
Publikováno v:
Cancers; Volume 15; Issue 8; Pages: 2263
Osimertinib is a third-generation epidermal growth factor receptor and tyrosine kinase inhibitor (EGFR-TKI) approved for the treatment of lung adenocarcinoma patients harboring EGFR mutations. However, acquired resistance to this targeted therapy is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e02c4c4a1179011337686196a1d84e90